Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies
| Status: | Terminated |
|---|---|
| Conditions: | Cancer, Blood Cancer, Blood Cancer, Lymphoma, Hematology, Leukemia |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 4/17/2018 |
| Start Date: | December 2004 |
| End Date: | March 2007 |
The purpose of this trial is to determine if patients with hematologic diseases who have a
HLA 6/6 matched related donor and are not eligible for a standard myeloablative stem cell
transplant will have less severe graft versus host disease (GVHD), transplant related
mortality, and less graft failure when treated with a non-myeloablative T-cell depleted stem
cell transplant.
HLA 6/6 matched related donor and are not eligible for a standard myeloablative stem cell
transplant will have less severe graft versus host disease (GVHD), transplant related
mortality, and less graft failure when treated with a non-myeloablative T-cell depleted stem
cell transplant.
Our prior experience in the lab and in clinical trials with non-myeloablative HLA-matched and
mismatched transplant strategies have been remarkable for a low transplant related mortality
rate, but a still formidable risk of GVHD and graft rejection. In this trial, we have
incorporated a combination ex-vivo T-cell depletion strategy to prevent GVHD with vigorous in
vivo depletion of host (and to a lesser extent donor) T-cells to prevent graft rejection.
Patients will receive non-myeloablative conditioning with cyclophosphamide, thymoglobulin,
fludarabine, and thymic irradiation, followed by a T-cell depleted PBSC infusion.
Cyclosporine will be given for GVHD prophylaxis, and tapered beginning on day 35. Data from
our mouse model and previous clinical trials have demonstrated that this approach can induce
mixed chimerism without GVHD, with the potential for conversion of mixed chimerism to full
donor hematopoiesis following donor leukocyte infusions.
mismatched transplant strategies have been remarkable for a low transplant related mortality
rate, but a still formidable risk of GVHD and graft rejection. In this trial, we have
incorporated a combination ex-vivo T-cell depletion strategy to prevent GVHD with vigorous in
vivo depletion of host (and to a lesser extent donor) T-cells to prevent graft rejection.
Patients will receive non-myeloablative conditioning with cyclophosphamide, thymoglobulin,
fludarabine, and thymic irradiation, followed by a T-cell depleted PBSC infusion.
Cyclosporine will be given for GVHD prophylaxis, and tapered beginning on day 35. Data from
our mouse model and previous clinical trials have demonstrated that this approach can induce
mixed chimerism without GVHD, with the potential for conversion of mixed chimerism to full
donor hematopoiesis following donor leukocyte infusions.
Inclusion Criteria:
- Disease statue: NHL, HD, or MM that are chemorefractory or relapsed; CLL that is Rai
Stage III/IV, or lymphocyte doubling time of 6 months, or stage I/II that is resistant
to > 2 chemotherapy regimens; AML or ALL in 1st or subsequent remission with poor
prognostic features; CML in accelerated or blast phae; MDS with life-threatening
cytopenias; patients who have had a previous autologous or allogeneic bone marrow or
stem cell transplant; other hematologic disorders which allogeneic stem cell
transplantation is appropriate where the risk of conventional transplantation is
considered to be unacceptably high.
- Estimated disease-free survival of less than one year
- ECOG performance status of 0, 1, or 2
- HLA-genotypically or phenotypically matched (at A, B, DR loci) related donor
Exclusion Criteria:
- Patients who life expectancy is limited by diseases other than their hematologic
malignancy.
- Cardiac Disease: symptomatic congestive hearth failure, or RVG, or ejection fraction
of < 45%, active angina pectoris, or uncontrolled hypertension.
- Pulmonary Disease: severe chronic obstructive lung disease, or symptomatic restrictive
lung disease, or DLCO of < 50%.
- Renal Disease: serum creatinine > 2.0 mg/dl or creatinine clearance < 50 ml/min.
- Hepatic Disease: serum bilirubin > 2.0 mg/dl or alkaline phosphatase, SGOT or SGPT > 3
times normal.
- Neurologic Disease: symptomatic leukoencephalopathy, active CNS malignancy or other
neuropsychiatric abnormalities believed to preclude transplantation
- HIV or HTLV I antibody or Hepatitis B surface antigen positivity
- Uncontrolled infection
We found this trial at
1
site
Click here to add this to my saved trials
